Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21581607 | 0.93 | SCN9A (0.50) | SCN9AMAPTNPC1RAB9ACTSS | |
| SCHEMBL31089903 | 0.93 | SCN9A (0.48) | SCN9AMAPTNPC1RAB9ACTSS | |
| SCHEMBL21581618 | 0.93 | SCN9A (0.48) | SCN9AMAPTNPC1RAB9ACTSS | |
| SCHEMBL31089836 | 0.88 | SCN9A (0.49) | SCN9ACTSSCTSKGRM5HDAC4 | |
| SCHEMBL21581600 | 0.88 | SCN9A (0.55) | SCN9ANPC1RAB9ACTSSCTSK | |
| SCHEMBL21611225 | 0.88 | RAF1 (0.42) | SCN9A | |
| SCHEMBL31089725 | 0.86 | SCN9A (0.51) | SCN9ACTSSCTSKHDAC4HDAC1 | |
| SCHEMBL21611230 | 0.86 | AAK1 (0.39) | SCN9AMAPTCTSSCTSKABCB1 | |
| SCHEMBL21581621 | 0.86 | SCN9A (0.47) | SCN9AMAPTCTSSCTSKSMN1; SMN2 | |
| SCHEMBL21611234 | 0.85 | SCN9A (0.42) | SCN9AMAPTCTSSCTSKADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-09-17 | — | — | US | disclosed |
| EP-3853216-B1 | 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS | BIONOMICS LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | GABRE, GAP43, GRIN2A | SCN9A 687/4885MAPT 379/4885NPC1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.